Showing 381 - 400 results of 510 for search '"fatty liver disease"', query time: 0.09s Refine Results
  1. 381

    An Update on Less Invasive and Endoscopic Techniques Mimicking the Effect of Bariatric Surgery by Froukje J. Verdam, Ruben Schouten, Jan Willem Greve, Ger H. Koek, Nicole D. Bouvy

    Published 2012-01-01
    “…Obesity (BMI 30–35 kg/m2) and its associated disorders such as type 2 diabetes, nonalcoholic fatty liver disease, and cardiovascular disease have reached pandemic proportions worldwide. …”
    Get full text
    Article
  2. 382

    The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study by Michael P. Curry, Edward Tam, Caitlin Schneider, Noha Abdelgelil, Tarek Hassanien, Nezam H. Afdhal

    Published 2024-01-01
    “…Background and Aims. Nonalcoholic fatty liver disease is the leading cause of chronic liver disease globally and can progress to cirrhosis, liver failure, and liver cancer. …”
    Get full text
    Article
  3. 383

    Liver diseases (<i>Review of the Seventeenth Russian Gastroenterological Week proceedings, October, 10–12, 2011, Moscow</i>) by I. V. Mayev, A. N. Kazyulin, Yu. A. Kucheryavy, Ye. A. Mayevskaya

    Published 2012-06-01
    “…The most of publications (70,5%) has been devoted to etiopathogenesis, features of clinical pattern, diagnostics and treatment of acute and chronic viral hepatitis (2542 patients), liver cirrhoses (1338 patients), non-alcoholic fatty liver disease (1145 patients), toxic liver diseases (834 patients) that indicates medical and social impact of these diseases. …”
    Get full text
    Article
  4. 384

    Alleviating batch effects in cell type deconvolution with SCCAF-D by Shuo Feng, Liangfeng Huang, Anna Vathrakokoili Pournara, Ziliang Huang, Xinlu Yang, Yongjian Zhang, Alvis Brazma, Ming Shi, Irene Papatheodorou, Zhichao Miao

    Published 2024-12-01
    “…Applied to non-alcoholic fatty liver disease, SCCAF-D unveils meaningful insights into changes in cell proportions during disease progression.…”
    Get full text
    Article
  5. 385

    Nutrition Therapy for Liver Diseases Based on the Status of Nutritional Intake by Kenichiro Yasutake, Motoyuki Kohjima, Manabu Nakashima, Kazuhiro Kotoh, Makoto Nakamuta, Munechika Enjoji

    Published 2012-01-01
    “…The dietary intake of patients with nonalcoholic fatty liver disease (NAFLD) is generally characterized by high levels of carbohydrate, fat, and/or cholesterol, and these dietary patterns influence hepatic lipid metabolism in the patients. …”
    Get full text
    Article
  6. 386

    Triterpenoids from Chios Mastiha Resin Against MASLD—A Molecular Docking Survey by Nataša Milošević, Maja Milanović, Milica Medić Stojanoska, Varomyalin Tipmanee, Ilias Smyrnioudis, George V. Dedoussis, Nataša Milić

    Published 2025-01-01
    “…Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease without an approved pharmacological approach for its prevention/treatment. …”
    Get full text
    Article
  7. 387

    Platelet Counts and Liver Enzymes after Bariatric Surgery by Hans-Erik Johansson, Arvo Haenni, Björn Zethelius

    Published 2013-01-01
    “…Obesity is characterized by liver steatosis, chronic inflammation, and increased liver enzymes, that is, gamma-glutamyltransferase (GGT) and alanine aminotransferase (ALT), markers for nonalcoholic fatty liver disease (NAFLD) and liver fat content. Increased platelet counts (PCs) are associated with inflammatory conditions and are a valuable biomarker of the degree of fibrosis in NAFLD. …”
    Get full text
    Article
  8. 388

    Herbicide Widespread: The Effects of Pethoxamid on Nonalcoholic Fatty Liver Steatosis In Vitro by Anna Virginia Adriana Pirozzi, Antonietta Stellavato, Chiara Schiraldi, Mariateresa Giuliano

    Published 2020-01-01
    “…Due to similarities to glyphosate, we did look at the effect of pethoxamid on impaired liver cells HepG2, using a nonalcoholic fatty liver disease (NAFLD) cell model in vitro. Pethoxamid was cytotoxic starting at 1 ppm. …”
    Get full text
    Article
  9. 389

    Early disease detection expert system development: primary machining software applications and dependences by A. S. Serobabov, E. V. Chebanenko, L. A. Denisova, T. S. Krolevets

    Published 2018-09-01
    “…The article observes descriptive statistics tools for the biomedical information processing, clinical trials data on the nonalcoholic fatty liver disease (NAFLD). The primary machining software package structure which characterizes patienthood including the laboratory studies results, co-morbidity, patient’s physiological parameters is elaborated. …”
    Get full text
    Article
  10. 390

    Effects of natural products on macrophage immunometabolism: A new frontier in the treatment of metabolic diseases by Jiani Li, Chen Guo, Xiaofei Yang, Weinan Xie, Wenjing Mi, Chenglong Hua, Cheng Tang, Han Wang

    Published 2025-03-01
    “…Dysregulation of macrophage immunometabolism has been closely implicated in several metabolic diseases, including obesity, type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), hypertension, atherosclerosis, and gout, which positions macrophages as potential therapeutic targets. …”
    Get full text
    Article
  11. 391

    Digital health technologies for metabolic disorders in older adults: a scoping review protocol by Michael Brändle, Elgar Fleisch, Tobias Kowatsch, Panitda Huynh, Mia Jovanova

    Published 2024-12-01
    “…Introduction Metabolic disorders (type 2 diabetes, insulin resistance, hyperglycaemia, obesity, hyperlipidaemia, hypertension, non-alcoholic fatty liver disease and metabolic syndrome) are leading causes of mortality and disability worldwide. …”
    Get full text
    Article
  12. 392

    Liver fibrosis and markers of endothelial function at metabolic syndrome and early disorders of carbohydrate metabolism by L. V. Chesnokova, I. M. Petrov, Ye. A. Sidorova, I. A. Troshina, Yu. A. Petrova

    Published 2014-12-01
    “…Complex estimation of endothelial function at non-alcoholic fatty liver disease (NAFLD) in association with early disorders of carbohydrate metabolism, in relation to liver fibrosis severity.Material and methods. …”
    Get full text
    Article
  13. 393

    Incidence rate and associated patient characteristics of liver disease in Wales 2004–2022: a retrospective population-scale observational study by Ashley Akbari, Andrew Yeoman, Haroon Ahmed, Jingwei Gao, Aled Davies, Thomas Peter Ignatius Pembroke

    Published 2025-02-01
    “…A total of 79 992 individuals (72%) entered the cohort with the underlying aetiology of liver disease, including alcohol-related liver disease, non-alcoholic fatty liver disease (NAFLD), viral hepatitis, metabolic, haemochromatosis and autoimmune liver diseases. …”
    Get full text
    Article
  14. 394

    Lipid-lowering Efficacy of Plant Proteins and Their Application Potential by Yue WANG, Chunhua GUAN, Hong BI, Fengyating WU, Yanqin SHEN, Liang TAO, Yang TIAN

    Published 2025-01-01
    “…In recent years, there has been a gradual increase in the prevalence of obesity, hyperlipidaemia, coronary atherosclerosis, non-alcoholic fatty liver disease, and other conditions attributed to shifts in dietary patterns. …”
    Get full text
    Article
  15. 395

    BMI trajectories are associated with NAFLD and advanced fibrosis via aging-inflammation mediation by Haiyang Peng, Zhibo Zhao, Jianping Gong, Kun He

    Published 2025-01-01
    “…Abstract Background As the global epidemic of obesity fuels metabolic conditions, the burden of nonalcoholic fatty liver disease (NAFLD) will become enormous. Abundant studies revealed the association between high body mass index (BMI) and NAFLD but overlooked the BMI patterns across life stages. …”
    Get full text
    Article
  16. 396

    Prevalence of digestive diseases in patients with excessive body weight and obesity (<i>according to data of polyclinic department of versatile clinic</i>) by I. R. Popova

    Published 2012-09-01
    “…Of diseases of digestive organs the most frequent were: non-alcoholic fatty liver disease (NAFLD) – 83,4 % (r=0,35, p&lt;0,001), non-alcoholic steatohepatitis (NASH) – 13,1% (r=0,14, p&lt;0,001), gallstone disease (GSD) – 41,8 % (r=0,05, p &lt;0,05); steatosis of the pancreas – 86,4% (r=0,20, р&lt;0,001). …”
    Get full text
    Article
  17. 397

    LAPORAN KASUS: ANALISIS KOMBINASI PENGGUNAAN HEPATOPROTEKTOR PADA CEDERA HATI KARENA INFEKSI BAKTERI STREPTOCOCCUS VIRIDANS by Muhammad Hasan Andryanto, Fauna Herawati, Umi Fatmawati

    Published 2024-11-01
    “…Penyakit CAP memiliki prevalensi non-alcohol-related fatty liver disease (NAFLD) yang lebih tinggi. Peningkatan kadar lemak di hati secara terus-menerus yang dipicu oleh penyakit pneumonia dapat menyebabkan peradangan di hati, hal tersebut menyebabkan penurunan fungsi hati dengan cepat dan mengakibatkan peningkatan kadar aspartate aminotransferase (AST), alanine aminotransferase (ALT), dan bilirubin total. …”
    Get full text
    Article
  18. 398

    Kupffer Cells Promote the Differentiation of Adult Liver Hematopoietic Stem and Progenitor Cells into Lymphocytes via ICAM-1 and LFA-1 Interaction by Deping Meng, Yuhong Qin, Nan Lu, Keke Fang, Yuan Hu, Zhigang Tian, Cai Zhang

    Published 2019-01-01
    “…These findings provide important insight into understanding liver extramedullary hematopoiesis and its significance, particularly under the state of some liver diseases, such as hepatitis, nonalcoholic fatty liver disease (NAFLD), and hepatocellular carcinoma (HCC).…”
    Get full text
    Article
  19. 399

    Влияние курсового приема L-орнитин- L-аспартата на фиброз и стеатоз печени у больных ассоциированной с нарушениями метаболизма жировой болезнью печени (неалкогольной жировой болезн... by Е. V. Garanina

    Published 2021-12-01
    “…Hyperammonaemia develops both in cirrhosis and earlier fibrotic stages during metabolic-associated fatty liver disease (MAFLD). Besides neurotropic, ammonia exerts the hepatotoxic and profibrotic effects. …”
    Get full text
    Article
  20. 400

    Correlation between Helicobacter pylori Infection and Metabolic Abnormality in General Population: A Cross-Sectional Study by Li-juan Lu, Ning-Bo Hao, Jian-Jun Liu, Xue Li, Rui-Ling Wang

    Published 2018-01-01
    “…For each individual, the following data were collected: age, gender, alanine transaminase (ALT), total protein, albumin, cholesterol, triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), urea nitrogen, creatinine, uric acid, fasting plasma glucose, postprandial blood sugar, nonalcoholic fatty liver disease (NAFLD), and bone mineral density (BMD). …”
    Get full text
    Article